Incisive Genetics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $9.4M

  • Investors
  • 10

Incisive Genetics General Information

Description

Developer of a lipid nanoparticle delivery platform designed to effectively and safely deliver gene-editing machinery to the site of application. The company develops transformational lipid nanoparticle-based gene-editing platforms for genetic therapies and provides an effective CRISPR-based gene therapy, enabling pharmaceutical businesses to conveniently deliver drugs to patients without causing any harm.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 200 - 980 George Street
  • Vancouver, British Columbia V6A 0H9
  • Canada
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Vertical(s)
Corporate Office
  • 200 - 980 George Street
  • Vancouver, British Columbia V6A 0H9
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Incisive Genetics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Seed Round 27-Jun-2022 $9.4M Completed Generating Revenue
4. Angel (individual) 12-Jul-2021 Completed Generating Revenue
3. Angel (individual) 22-Sep-2020 Completed Startup
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 01-Jan-2018 Completed Startup
To view Incisive Genetics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Incisive Genetics Patents

Incisive Genetics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026028149-A1 Guide rnas for editing serpina1, and compositions and methods relating thereto Pending 01-Aug-2024
AU-2025376352-A1 Dual guide rnas for allele-selective or specific gene editing, and compositions and methods relating thereto Pending 14-May-2024
WO-2025238579-A1 Dual guide rnas for allele-selective or specific gene editing, and compositions and methods relating thereto Pending 14-May-2024
AU-2025378053-A1 Guide rnas for allele-selective gene editing, and compositions and methods relating thereto Pending 14-May-2024
WO-2025238578-A1 Guide rnas for allele-selective gene editing, and compositions and methods relating thereto Pending 14-May-2024 C12N15/907
To view Incisive Genetics’s complete patent history, request access »

Incisive Genetics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Incisive Genetics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Conconi Growth Partners Family Office Minority
MacHall Group Other Minority
Robinson Sauder Family Office Family Office Minority
Saltagen Ventures Venture Capital Minority
Velocity Capital Management PE/Buyout Minority
You’re viewing 5 of 10 investors. Get the full list »

Incisive Genetics FAQs

  • When was Incisive Genetics founded?

    Incisive Genetics was founded in 2018.

  • Where is Incisive Genetics headquartered?

    Incisive Genetics is headquartered in Vancouver, Canada.

  • What is the size of Incisive Genetics?

    Incisive Genetics has 13 total employees.

  • What industry is Incisive Genetics in?

    Incisive Genetics’s primary industry is Drug Delivery.

  • Is Incisive Genetics a private or public company?

    Incisive Genetics is a Private company.

  • What is Incisive Genetics’s current revenue?

    The current revenue for Incisive Genetics is .

  • How much funding has Incisive Genetics raised over time?

    Incisive Genetics has raised $12.2M.

  • Who are Incisive Genetics’s investors?

    Conconi Growth Partners, MacHall Group, Robinson Sauder Family Office, Saltagen Ventures, and Velocity Capital Management are 5 of 10 investors who have invested in Incisive Genetics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process